Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy

Pragya Srivastava, Benjamin E. Paluch, Junko Matsuzaki, Smitha R. James, Golda Collamat-Lai, Nadja Blagitko-Dorfs, Laurie Ann Ford, Rafeh Naqash, Michael Lübbert, Adam R Karpf, Michael J. Nemeth, Elizabeth A. Griffiths

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Cancer testis antigens (CTAs) are promising cancer associated antigens in solid tumors, but in acute myeloid leukemia, dense promoter methylation silences their expression. Leukemia cell lines exposed to HMAs induce expression of CTAs. We hypothesized that AML patients treated with standard of care decitabine (20mg/m2 per day for 10 days) would demonstrate induced expression of CTAs. Peripheral blood blasts serially isolated from AML patients treated with decitabine were evaluated for CTA gene expression and demethylation. Induction of NY-ESO-1 and MAGEA3/A6, were observed following decitabine. Re-expression of NY-ESO-1 and MAGEA3/A6 was associated with both promoter specific and global (LINE-1) hypomethylation. NY-ESO-1 and MAGEA3/A6 mRNA levels were increased irrespective of clinical response, suggesting that these antigens might be applicable even in patients who are not responsive to HMA therapy. Circulating blasts harvested after decitabine demonstrate induced NY-ESO-1 expression sufficient to activate NY-ESO-1 specific CD8+ T-cells. Induction of CTA expression sufficient for recognition by T-cells occurs in AML patients receiving decitabine. Vaccination against NY-ESO-1 in this patient population is feasible.

Original languageEnglish (US)
Pages (from-to)12840-12856
Number of pages17
JournalOncotarget
Volume7
Issue number11
DOIs
StatePublished - Mar 15 2016

Fingerprint

decitabine
Testicular Neoplasms
Acute Myeloid Leukemia
Antigens
T-Lymphocytes
Standard of Care
Methylation
Neoplasms
Leukemia
Vaccination
Gene Expression
Cell Line
Messenger RNA

Keywords

  • Acute myeloid leukemia
  • Cancer testis antigen
  • Decitabine
  • Immunotherapy
  • Ny-ESO-1

ASJC Scopus subject areas

  • Oncology

Cite this

Srivastava, P., Paluch, B. E., Matsuzaki, J., James, S. R., Collamat-Lai, G., Blagitko-Dorfs, N., ... Griffiths, E. A. (2016). Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget, 7(11), 12840-12856. https://doi.org/10.18632/oncotarget.7326

Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. / Srivastava, Pragya; Paluch, Benjamin E.; Matsuzaki, Junko; James, Smitha R.; Collamat-Lai, Golda; Blagitko-Dorfs, Nadja; Ford, Laurie Ann; Naqash, Rafeh; Lübbert, Michael; Karpf, Adam R; Nemeth, Michael J.; Griffiths, Elizabeth A.

In: Oncotarget, Vol. 7, No. 11, 15.03.2016, p. 12840-12856.

Research output: Contribution to journalArticle

Srivastava, P, Paluch, BE, Matsuzaki, J, James, SR, Collamat-Lai, G, Blagitko-Dorfs, N, Ford, LA, Naqash, R, Lübbert, M, Karpf, AR, Nemeth, MJ & Griffiths, EA 2016, 'Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy', Oncotarget, vol. 7, no. 11, pp. 12840-12856. https://doi.org/10.18632/oncotarget.7326
Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Blagitko-Dorfs N et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016 Mar 15;7(11):12840-12856. https://doi.org/10.18632/oncotarget.7326
Srivastava, Pragya ; Paluch, Benjamin E. ; Matsuzaki, Junko ; James, Smitha R. ; Collamat-Lai, Golda ; Blagitko-Dorfs, Nadja ; Ford, Laurie Ann ; Naqash, Rafeh ; Lübbert, Michael ; Karpf, Adam R ; Nemeth, Michael J. ; Griffiths, Elizabeth A. / Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. In: Oncotarget. 2016 ; Vol. 7, No. 11. pp. 12840-12856.
@article{58c9ec0c798a4564bdca02d94650fee5,
title = "Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy",
abstract = "Cancer testis antigens (CTAs) are promising cancer associated antigens in solid tumors, but in acute myeloid leukemia, dense promoter methylation silences their expression. Leukemia cell lines exposed to HMAs induce expression of CTAs. We hypothesized that AML patients treated with standard of care decitabine (20mg/m2 per day for 10 days) would demonstrate induced expression of CTAs. Peripheral blood blasts serially isolated from AML patients treated with decitabine were evaluated for CTA gene expression and demethylation. Induction of NY-ESO-1 and MAGEA3/A6, were observed following decitabine. Re-expression of NY-ESO-1 and MAGEA3/A6 was associated with both promoter specific and global (LINE-1) hypomethylation. NY-ESO-1 and MAGEA3/A6 mRNA levels were increased irrespective of clinical response, suggesting that these antigens might be applicable even in patients who are not responsive to HMA therapy. Circulating blasts harvested after decitabine demonstrate induced NY-ESO-1 expression sufficient to activate NY-ESO-1 specific CD8+ T-cells. Induction of CTA expression sufficient for recognition by T-cells occurs in AML patients receiving decitabine. Vaccination against NY-ESO-1 in this patient population is feasible.",
keywords = "Acute myeloid leukemia, Cancer testis antigen, Decitabine, Immunotherapy, Ny-ESO-1",
author = "Pragya Srivastava and Paluch, {Benjamin E.} and Junko Matsuzaki and James, {Smitha R.} and Golda Collamat-Lai and Nadja Blagitko-Dorfs and Ford, {Laurie Ann} and Rafeh Naqash and Michael L{\"u}bbert and Karpf, {Adam R} and Nemeth, {Michael J.} and Griffiths, {Elizabeth A.}",
year = "2016",
month = "3",
day = "15",
doi = "10.18632/oncotarget.7326",
language = "English (US)",
volume = "7",
pages = "12840--12856",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

TY - JOUR

T1 - Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy

AU - Srivastava, Pragya

AU - Paluch, Benjamin E.

AU - Matsuzaki, Junko

AU - James, Smitha R.

AU - Collamat-Lai, Golda

AU - Blagitko-Dorfs, Nadja

AU - Ford, Laurie Ann

AU - Naqash, Rafeh

AU - Lübbert, Michael

AU - Karpf, Adam R

AU - Nemeth, Michael J.

AU - Griffiths, Elizabeth A.

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Cancer testis antigens (CTAs) are promising cancer associated antigens in solid tumors, but in acute myeloid leukemia, dense promoter methylation silences their expression. Leukemia cell lines exposed to HMAs induce expression of CTAs. We hypothesized that AML patients treated with standard of care decitabine (20mg/m2 per day for 10 days) would demonstrate induced expression of CTAs. Peripheral blood blasts serially isolated from AML patients treated with decitabine were evaluated for CTA gene expression and demethylation. Induction of NY-ESO-1 and MAGEA3/A6, were observed following decitabine. Re-expression of NY-ESO-1 and MAGEA3/A6 was associated with both promoter specific and global (LINE-1) hypomethylation. NY-ESO-1 and MAGEA3/A6 mRNA levels were increased irrespective of clinical response, suggesting that these antigens might be applicable even in patients who are not responsive to HMA therapy. Circulating blasts harvested after decitabine demonstrate induced NY-ESO-1 expression sufficient to activate NY-ESO-1 specific CD8+ T-cells. Induction of CTA expression sufficient for recognition by T-cells occurs in AML patients receiving decitabine. Vaccination against NY-ESO-1 in this patient population is feasible.

AB - Cancer testis antigens (CTAs) are promising cancer associated antigens in solid tumors, but in acute myeloid leukemia, dense promoter methylation silences their expression. Leukemia cell lines exposed to HMAs induce expression of CTAs. We hypothesized that AML patients treated with standard of care decitabine (20mg/m2 per day for 10 days) would demonstrate induced expression of CTAs. Peripheral blood blasts serially isolated from AML patients treated with decitabine were evaluated for CTA gene expression and demethylation. Induction of NY-ESO-1 and MAGEA3/A6, were observed following decitabine. Re-expression of NY-ESO-1 and MAGEA3/A6 was associated with both promoter specific and global (LINE-1) hypomethylation. NY-ESO-1 and MAGEA3/A6 mRNA levels were increased irrespective of clinical response, suggesting that these antigens might be applicable even in patients who are not responsive to HMA therapy. Circulating blasts harvested after decitabine demonstrate induced NY-ESO-1 expression sufficient to activate NY-ESO-1 specific CD8+ T-cells. Induction of CTA expression sufficient for recognition by T-cells occurs in AML patients receiving decitabine. Vaccination against NY-ESO-1 in this patient population is feasible.

KW - Acute myeloid leukemia

KW - Cancer testis antigen

KW - Decitabine

KW - Immunotherapy

KW - Ny-ESO-1

UR - http://www.scopus.com/inward/record.url?scp=84962909333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962909333&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7326

DO - 10.18632/oncotarget.7326

M3 - Article

VL - 7

SP - 12840

EP - 12856

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -